Ajanta Pharma is firmly positioned as a meaningful niche player in the US generics market.
Our strategy is to have a selective play in this market with launching limited competition products. Currently we have 54 ANDA approvals, out of which 50 are commercialized. Ajanta is awaiting US FDA approval for 22 ANDAs. We plan to file 8-12 ANDAs every year. All the products are marketed through our subsidiary Ajanta Pharma USA Inc.
Our commitment for the market was evident during a critical drug shortage when we airlifted medicines for paediatric patients battling influenza, saving lives when it mattered most. These achievements matter because ultimately, Ajanta’s goal is to attain good health for all.
We continue to work with all major distributors in the market with an impeccable service record which has strengthened our position as a partner of first choice. We have received DIANA award 5 times for ‘Best Overall Generic Manufacturer’ in less than $100 million category. We also received ‘HDA Manufacturer Partner of the Year' award recently.
For more details on this subsidiary, please click here.
